Progression-Free Survival: Pros and Cons

John Bazar outlines PFS as a surrogate endpoint, its suitability in metastatic and indolent diseases, and assessment via RECIST.

Play episode from 04:46

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!